Biodesix, Inc.

Biodesix, Inc. is a data-driven diagnostic solutions provider operating across the United States. Its primary focus includes a comprehensive suite of blood-based lung tests, marketed as the Nodify Lung Nodule Risk Assessment (which includes Nodify XL2 and Nodify CDT). These assessments enable clinicians to evaluate the risk of lung cancer in patients with suspicious nodules, aiding in the reclassification of malignancy risk and guiding appropriate treatment pathways. Beyond risk assessment, Biodesix offers additional lung cancer diagnostics such as GeneStrat ddPCR, which detects specific tumor mutations, and VeriStrat, which gauges the patient's immune system status. Both are crucial for establishing prognosis and informing treatment plans. Another offering is the GeneStrat NGS (Next-Generation Sequencing) test, a rapid, blood-based sequencing solution providing results within 72 hours. Through a partnership with Bio-Rad Laboratories, Inc., Biodesix also provides COVID-19 testing services under its Biodesix WorkSafe program, featuring the Bio-Rad SARS-CoV-2 ddPCR test and the Platelia SARS-CoV-2 Total Ab test, an antibody assay for detecting a B-cell immune response indicating recent or prior infection. Furthermore, the company extends its expertise to biopharmaceutical companies, offering diagnostic and clinical research services, alongside clinical trial testing. It also actively discovers, develops, and commercializes companion diagnostics. Originally incorporated as Elston Technologies, Inc. in 2005, Biodesix, Inc. maintains its headquarters in Boulder, Colorado.

業界

Medical - Diagnostics & Research

セクター

Healthcare

本社

US

最高経営責任者（CEO）

Scott Hutton

上場以来

2020年10月28日

従業員

334

Biodesix, Inc. is a data-driven diagnostic solutions provider operating across the United States. Its primary focus includes a comprehensive suite of blood-based lung tests, marketed as the Nodify Lung Nodule Risk Assessment (which includes Nodify XL2 and Nodify CDT). These assessments enable clinicians to evaluate the risk of lung cancer in patients with suspicious nodules, aiding in the reclassification of malignancy risk and guiding appropriate treatment pathways. Beyond risk assessment, Biodesix offers additional lung cancer diagnostics such as GeneStrat ddPCR, which detects specific tumor mutations, and VeriStrat, which gauges the patient's immune system status. Both are crucial for establishing prognosis and informing treatment plans. Another offering is the GeneStrat NGS (Next-Generation Sequencing) test, a rapid, blood-based sequencing solution providing results within 72 hours. Through a partnership with Bio-Rad Laboratories, Inc., Biodesix also provides COVID-19 testing services under its Biodesix WorkSafe program, featuring the Bio-Rad SARS-CoV-2 ddPCR test and the Platelia SARS-CoV-2 Total Ab test, an antibody assay for detecting a B-cell immune response indicating recent or prior infection. Furthermore, the company extends its expertise to biopharmaceutical companies, offering diagnostic and clinical research services, alongside clinical trial testing. It also actively discovers, develops, and commercializes companion diagnostics. Originally incorporated as Elston Technologies, Inc. in 2005, Biodesix, Inc. maintains its headquarters in Boulder, Colorado.

業界

Medical - Diagnostics & Research

セクター

Healthcare

本社

US

最高経営責任者（CEO）

Scott Hutton

上場以来

2020年10月28日

従業員

334